Deriving clinical action from whole-genome analysis

Personalized Medicine

Volumn 9, Issue 3, 2012, Pages 247-252

  Wall, Dennis P ^a   Tonellato, Peter J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

clinical genomics; clinical variants; clinical whole genome analysis; clinically actionable variation; genomic medicine; genomic pathology; whole genome analysis

Indexed keywords

BEVACIZUMAB; CETUXIMAB; DNA; PANITUMUMAB; RNA;

ACUTE GRANULOCYTIC LEUKEMIA; FOOD AND DRUG ADMINISTRATION; GENE CONTROL; GENE DOSAGE; GENE EXPRESSION; GENE MUTATION; GENETIC HETEROGENEITY; GENOME ANALYSIS; HIGH THROUGHPUT SEQUENCING; HUMAN; LABORATORY TEST; NOTE; ONCOGENE; PATHOLOGY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR DIAGNOSIS; WHOLE GENOME ANALYSIS;

EID: 84860736773     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.12.32     Document Type: Note

References (28)

1. Dias-Santagata D, Akhavanfard S, David SS et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol. Med. 2(5), 146-158 (2010).
2. MacConaill LE, Campbell CD, Kehoe SM et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS ONE 4(11), e7887 (2009).
3. Macconaill LE, Garraway LA. Clinical implications of the cancer genome. J. Clin. Oncol. 28(35), 5219-5228 (2010).
4. Taylor BS, Ladanyi M. Clinical cancer genomics: how soon is now? J. Pathol. 223(2), 318-326 (2011).
5. Lupski JR, Reid JG, Gonzaga-Jauregui C et al. Whole-genome sequencing in a patient with charcot-marie-tooth neuropathy. N. Engl. J. Med. 362(13), 1181-1191 (2010).
6. Welch JS, Westervelt P, Ding L et al. Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA 305(15), 1577-1584 (2011).
7. Link DC, Schuettpelz LG, Shen D et al. Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML. JAMA 305(15), 1568-1576 (2011).
8. Worthey EA, Mayer AN, Syverson GD et al. Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease. Genet. Med. 13(3), 255-262 (2011).
9. Jones SJ, Laskin J, Li YY et al. Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. Genome Biol. 11(8), R82 (2010).
10. Crawford JM, Aspinall G. The business value and cost effectiveness of genomic medicine. Per. Med. 9(3) 265-286 (2012).
11. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366(10), 883-892 (2012).
12. Tonellato PJ, Crawford JM, Boguski MS, Saffitz JE. A national agenda for the future of pathology in personalized medicine: report of the proceedings of a meeting at the Banbury conference center on genome-era pathology, precision diagnostics, and preemptive care: a stakeholder summit. Am. J. Clin. Pathol. 135(5), 668-672 (2011).
13. Walcoff SD, Pfeifer JD. Modernizing US regulatory and reimbursement policy to support continued innovation in genomic pathology: challenges and opportunities for personalized medicine. Per. Med. 9(3) 295-252 (2012).
14. Kohane IS, Hsing M, Kong SW. Taxonomizing, sizing, and overcoming the incidentalome. Genet. Med. 14(4), 399-404 (2012).
15. Kohane IS. (Mis)treating the pharmacogenetic incidentalome. Nat. Rev. Drug Discov. 11(2), 89-90 (2012).
16. Agaram NP, Wong GC, Guo T et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer 47(10), 853-859 (2008).
17. Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363(9), 809-819 (2010).
18. Heinrich MC, Maki RG, Corless CL et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J. Clin. Oncol. 26(33), 5352-5359 (2008).
19. Carvajal RD, Antonescu CR, Wolchok JD et al. KIT as a therapeutic target in metastatic melanoma. JAMA 305(22), 2327-2334 (2011).
20. Antonescu CR, Busam KJ, Francone TD et al. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int. J. Cancer 121(2), 257-264 (2007). (Pubitemid 46917693)
21. Terheyden P, Houben R, Pajouh P, Thorns C, Zillikens D, Becker JC. Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene. J. Invest. Dermatol. 130(1), 314-316 (2010).
22. Buti S, Donini M, Sergio P et al. Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma. J. Clin. Oncol. 29(33), E803-E805 (2011).
23. Heinrich MC, Corless CL, Demetri GD et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21(23), 4342-4349 (2003). (Pubitemid 46621810)
24. Han SW, Kim TY, Hwang PG et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J. Clin. Oncol. 23(11), 2493-2501 (2005).
25. Kobayashi S, Boggon TJ, Dayaram T et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352(8), 786-792 (2005). (Pubitemid 40271173)
26. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129-2139 (2004). (Pubitemid 38637993)
27. Rosell R, Moran T, Cardenal F et al. Predictive biomarkers in the management of EGFR mutant lung cancer. Ann. NY Acad. Sci. 1210, 45-52 (2010).
28. Walsh T, Lee MK, Casadei S et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc. Natl Acad. Sci. USA 107(28), 12629-12633 (2010)